HTA170 Including Decision-Analytic Benefit-Harm Evaluation in HTA - Different Age Ranges and Screening Intervals in Breast Cancer Screening in Germany

G Sroczynski,LR Hallsson, N Mühlberger, F Kuehne,B Jahn, H Kölsch, S Sauerland, K Angelescu, U Siebert

Value in Health（2022）

引用 0|浏览0

暂无评分

摘要

To complement an IQWiG benefit assessment, we conducted a decision-analytic modelling study to evaluate the long-term benefits and harms of extending the age ranges for breast cancer (BC) screening with mammography in Germany compared to current biennial BC screening age 50-69 years.

查看译文

关键词

breast cancer screening,hta170,breast cancer,decision-analytic,benefit-harm

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要